SUNNYVALE, Calif., June 16 /PRNewswire/ -- CardioGenesis (Nasdaq: CGCP), a
leader in transmyocardial revascularization (TMR) technology, today announced
the appointment of Gary M. Saxton as Vice President, Marketing. Mr. Saxton
will be responsible for the management of CardioGenesis' worldwide marketing
operations reporting to Allen W. Hill, President and Chief Executive Officer.
Most recently, Mr. Saxton was Director, Dealer Management for Medtronic Inc.,
where he was responsible for developing and managing the distribution/dealer
strategy in Japan. Prior to this position he was Director, Strategic Plan,
where he led the corporate strategic planning efforts at Medtronic, reporting
to the Vice Chairman. He joined Medtronic as the Market Development Manager
in the Bradycardia Pacing business unit.
Commenting on the appointment, Allen W. Hill, President and Chief
Financial Officer at CardioGenesis, said, "We are very pleased to have Gary
join our team. He comes to us with broad strategic marketing and corporate
development experience in the medical and medical device business. Gary's
knowledge of U.S. and international medical device markets coupled with his
operational and strategic focus will provide important management and
leadership capabilities."
Prior to joining Medtronic, Mr. Saxton was in the corporate strategy
department of IBM Corporation. He also spent three years in Asia Pacific with
IBM in a variety of marketing and strategic planning roles. He joined IBM as
a Marketing Representative. He holds a B.S. degree from the United States
Military Academy, West Point, N.Y., and an MBA from Harvard University,
Boston, Mass.
CardioGenesis Corporation, based in Sunnyvale, Calif., develops,
manufactures and markets proprietary systems including disposable products, to
perform intraoperative transmyocardial revascularization, catheter-based
percutaneous myocardial revascularization, and thoracoscopic transmyocardial
revascularization, to treat patients afflicted with debilitating angina.
CardioGenesis catheter systems and probes deliver laser energy to create
channels in oxygen-deprived (ischemic) regions of the heart muscle
(myocardium). CardioGenesis holds patents for the system and method of
percutaneous myocardial revascularization, U.S. Patent Number 5,389,096; the
method of intraoperative myocardial device revascularization, U.S. Patent
Number 5,380,316; and other patents in the field of transmyocardial
revascularization. For more information on the company and its products,
visit the CardioGenesis web site at http://www.cardiogenesis.com.
SOURCE CardioGenesis Corporation
 back to top
Related links:
http://www.cardiogenesis.com
CONTACT:
Allen W. Hill, President and CEO, or Richard
P. Powers, Vice President and CFO, 408-328-8500, both of
CardioGenesis; or Kate Rajeck, Analyst Contact, or Ann Trunko,
General Information, 415-986-1591, both of The Financial
Relations Board
|
